Open calls for funding

IHI call 8 is a two-stage call with topics on cardiovascular disease, osteoarthritis, regulatory sandboxes, and patient-centred endpoints.

Topics

• Topic 1: A city-based approach to reducing cardiovascular mortality in Europe
• Topic 2: Novel endpoints for osteoarthritis (OA) by applying big data analytics
• Topic 3: Modelling regulatory sandbox mechanisms and enabling their deployment to support breakthrough innovation
• Topic 4: Patient-centred clinical-study endpoints derived using digital health technologies

Deadline: 10 October 2024 (short proposal); 23 April 2025 (full proposal)

More information

EU-ATTRACT 2025: International call for research proposals on rare cancer drug development ATTRACT Cancer drug research

ATTRACT is the first international initiative to accelerate drug development for rare cancers by funding cross-border clinical academic research. Building on the success of the first edition, we are excited to announce the launch of a second call for projects in September 2024.

Six European anticancer charities join forces and launch the ATTRACT 2025 call to stimulate international research on the treatment of rare cancers. We invite European researchers and clinicians from different countries to unite and collaborate in setting up late phase (phase 2/3) international clinical trials that aim to advance the development of better drug therapy for rare cancers patients.

Application open: 09 September 2024

Deadline: 11 October 2024 (pre-proposal); End of April 2025 (full proposal)

More information

This call fits within the ‘Smart Flanders’ theme and focuses on projects that aim to strengthen research and innovation capacity.

Budget: 5.000.000 euros (1.500.000 / project)
Deadline: 18 November 2024 (pre-proposal), 07 February 2025 (full proposal)

More information

The Global Innovation Fund (GIF) is a non-profit, impact-first investment fund headquartered in London with offices in Washington, D.C., Nairobi and Singapore. It invests in the development, rigorous testing, and scaling of innovations targeted at improving the lives of the world’s poorest people. GIF believes that the best ideas for solving some of the world’s most critical problems can come from anyone, anywhere. Through its grants and risk capital, the Fund helps breakthrough solutions to global development challenges from for-profit firms, non-profit organisations, researchers, and government agencies to maximise their impact and affect meaningful change.

GIF supports innovations on their path to scale and therefore supports innovators in a staged funding approach from early-stage field pilots (with funding up to 230K USD) right through to large-scale implementation (up to 15M USD). Innovations must be focussed on those living in poverty and ready to be applied in a real-word setting. The innovations must be informed by evidence and generate new knowledge on what works. Theoretical research, or purely lab-based activities that are not linked to implementation are not eligible for funding. 

More information

KOTK funds psychosocial research and implementation projects that introduce something new in the care of (ex-)cancer patients or substantially improve existing care. Funding can be in the form of seed money or project money.

Deadlines: 13 January 2025, 10 March 2025, 26 May 2025, 25 August 2025, 9 October 2025

More information

Financial support for an ongoing or envisioned collaborative project in genetic diseases between a research team/consortium of research teams in Belgium and a team from the Institut Imagine France.

Budget: 100.000 euro
Deadline: 21 January 2025

More information

Financial support that allows an M.D. to develop (further) knowledge or tecnical skills in genetic research, thanks to targeted training at a centre of excellence in Belgium or at the Institut Imagine France.

Budget: 100.000 euro
Deadline: 21 January 2025

More information

An online information session for interested applicants is planned for 5th November 2024, 11:00-13:00. This session will combine presentations on the scope of the call and scientific and practical aspects of proposal development. There will be ample time for Q&A. Registration in advance, by sending an email to Benefit@zonmw.nl, is mandatory before Sunday 3rd November 2024 at 22:00.

What and for who?
The BeNeFIT call focuses on comparative effectiveness trials, in which Dutch and Belgian institutions jointly conduct non-commercial practice-oriented research, which show clear value for money and have the potential for return on investment in both Belgium and the Netherlands.

Those studies compare two treatment options (with ‘no treatment’ being one of the possible treatment options) that are already in use in clinical practice in a given indication in both Belgium and the Netherlands, but are not yet sufficiently directly compared (i.e. which of the two treatment options work best in daily practice). Accepted study interventions are not limited to drugs or medical devices but also include a broad range of interventions, such as psychotherapy, diet, diagnostic tests, surgery or ways to deliver health care. Proposals will be selected based on the need for evidence in clinical practice and possible efficiency improvement and potential return on investment for the Dutch and Belgian health care systems.

Research teams from institutions in Belgium and the Netherlands can apply to this call. The sponsor (the main applicant) should be located in one of the two countries and should be supported by a national coordinating centre in the other country.

Support of HIRUZ
Investigators from U(Z)Gent with a research proposal will have the support of the Clinical Trial Unit (CTU) of Health, Innovation and Research Institute (HIRUZ) to submit and perform the proposed clinical trial. For more information and support, please contact HIRUZ CTU via hiruz.ctu@uzgent.be or 09/332.09.08 (Joke Tommelein).

Deadline: 28 January 2025

More information

What and for who?
The BeNeFIT call focuses on comparative effectiveness trials, in which Dutch and Belgian institutions jointly conduct non-commercial practice-oriented research, which show clear value for money and have the potential for return on investment in both Belgium and the Netherlands.

Those studies compare two treatment options (with ‘no treatment’ being one of the possible treatment options) that are already in use in clinical practice in a given indication in both Belgium and the Netherlands, but are not yet sufficiently directly compared (i.e. which of the two treatment options work best in daily practice). Accepted study interventions are not limited to drugs or medical devices but also include a broad range of interventions, such as psychotherapy, diet, diagnostic tests, surgery or ways to deliver health care. Proposals will be selected based on the need for evidence in clinical practice and possible efficiency improvement and potential return on investment for the Dutch and Belgian health care systems.

Research teams from institutions in Belgium and the Netherlands can apply to this call. The sponsor (the main applicant) should be located in one of the two countries and should be supported by a national coordinating centre in the other country.

Support of HIRUZ
Investigators from U(Z)Gent with a research proposal will have the support of the Clinical Trial Unit (CTU) of Health, Innovation and Research Institute (HIRUZ) to submit and perform the proposed clinical trial. For more information and support, please contact HIRUZ CTU via hiruz.ctu@uzgent.be or 09/332.09.08 (Joke Tommelein).

Deadline: 28 January 2025

More information

Deadline: 30 January 2025

More information